Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

TwinTurboBul161 Aug. 3 at 11:31 PM

$FCHL $NEO Watching7

0 · Reply

bmwbuzzz Aug. 3 at 3:50 PM

$NEO Adding to my adding to the sentiment!!!

0 · Reply

bmwbuzzz Jul. 31 at 12:41 AM

$NEO Adding to the sentiment!

0 · Reply

BTG007 Jul. 30 at 5:56 PM

$NEO lawsuits plus they let go of their chief compliance officer- could spell trouble in the future

0 · Reply

Spicy_Trade Jul. 29 at 11:49 PM

NeoGenomics, Inc. ( $NEO ) SpicyTrade - Daily Stock Analysis https://youtu.be/mKBSi4bIVQw?si=eB_BSBcVgw68wnJT

0 · Reply

topstockalerts Jul. 29 at 8:06 PM

$NEO not chasing but definitely watching this closely

0 · Reply

Aatrader2475 Jul. 29 at 4:46 PM

$BATL $CMMB $MULN.X $NEO $SKYQ @FDI2026 what you got to say for your clown self??? LOL

0 · Reply

Stocks_Spot Jul. 29 at 4:22 PM

$NEO is drawing fresh interest on July 29 after a solid second-quarter update. NeoGenomics posted $202 million in revenue, up 11% year over year, with clinical revenue rising 14% and NGS revenue growing 26%. Adjusted EBITDA increased 36% to $14 million, and management raised 2026 guidance to $802-806 million in revenue and $56-58 million in adjusted EBITDA. The reaction makes sense, but the next test is whether the richer testing mix can keep lifting margins. GAAP net income was $2 million, yet it included an $11 million gain from debt extinguishment. The operating trend looks better, though headline profitability still needs context. Not financial advice. Do your own research.

0 · Reply

prismmarketview Jul. 29 at 4:21 PM

We are adding NeoGenomics (, NASDAQ: $NEO ) to the PRISM Emerging MedTech Index. NeoGenomics runs oncology diagnostics, from cancer genetics testing to liquid biopsy, for oncologists, pathologists, and hospital systems. Second quarter revenue rose 11% to $202 million. Next-generation sequencing revenue grew 26%, adjusted EBITDA rose 36%, and the company raised full year guidance. NeoGenomics also refinanced into $316 million of 0.75% convertible notes due 2032, with capped calls intended to limit dilution. They provide exposure to precision oncology diagnostics. https://prismmarketview.com/companies/neogenomics-inc/

0 · Reply

prismmarketview Jul. 29 at 4:16 PM

PRISM Mid-Day Movers: New Energy and MedTech are Today’s Leaders. Sky Quarry Inc. (NASDAQ: $SKYQ ) is higher today, with the stock up about 18% to 4.33 from a prior close of 3.67. NeoGenomics, Inc. (NASDAQ: $NEO ) is surging today, with the stock up about 15% to 15.44 from a prior close of 13.40. Other Notable Movers: Battalion Oil Corporation ( $BATL ) up 13% Chemomab Therapeutics ( $CMMB ) up 11% Mullen Automotive ( $MULN.X )down -19% Disclaimer: All stock prices, percentage changes, volumes, and other market data are approximate and reflect conditions as of July 29, 2026, at approximately 12:00 p.m. ET. Data is subject to change and is provided for informational purposes only, not as investment advice.

0 · Reply

NeoGenomics price target raised to $19 from $17 at Craig-Hallum

2026-07-29T11:26:59.000Z - 6 days ago

NeoGenomics price target raised to $19 from $15 at Needham

Jul 28, 2026, 4:30 PM EDT - 6 days ago

NeoGenomics Earnings Call Transcript: Q2 2026

Jul 28, 2026, 4:30 PM EDT - 6 days ago

NeoGenomics Earnings release: Q2 2026

Jul 28, 2026, 4:30 PM EDT - 6 days ago

NeoGenomics Quarterly report: Q2 2026

Jul 28, 2026, 4:30 PM EDT - 6 days ago

NeoGenomics Slides: Q2 2026

2026-07-28T20:25:58.000Z - 6 days ago

NeoGenomics reports Q2 EPS 5c, consensus 3c

2026-07-28T20:25:22.000Z - 6 days ago

NeoGenomics raises FY26 revenue view from $797M-$803M to $802M-$806M

Jul 28, 2026, 4:05 PM EDT - 6 days ago

NeoGenomics Reports Second Quarter 2026 Results

2026-07-24T11:55:45.000Z - 11 days ago

NeoGenomics price target raised to $16 from $11 at Benchmark

2026-07-20T21:30:16.000Z - 14 days ago

NeoGenomics announces settlement of voluntary disclosure to OIG-HHS

Jul 20, 2026, 5:23 PM EDT - 14 days ago

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

2026-07-15T12:50:28.000Z - 19 days ago

NeoGenomics price target raised to $19 from $14 at TD Cowen

2026-07-13T11:15:31.000Z - 22 days ago

NeoGenomics price target raised to $16 from $11 at BofA

2026-07-09T11:10:10.000Z - 26 days ago

NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic

Jul 9, 2026, 7:05 AM EDT - 26 days ago

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Jul 7, 2026, 7:05 AM EDT - 4 weeks ago

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

2026-06-25T11:10:49.000Z - 5 weeks ago

NeoGenomics appoints Starrett to its Board of Directors

Jun 25, 2026, 7:05 AM EDT - 5 weeks ago

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

2026-06-17T12:22:47.000Z - 6 weeks ago

NeoGenomics announces pricing of $275M convertible senior notes offering

Jun 17, 2026, 6:00 AM EDT - 6 weeks ago

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

2026-06-15T21:31:22.000Z - 7 weeks ago

NeoGenomics files to sell $275M of convertible senior notes due 2032

Jun 15, 2026, 5:24 PM EDT - 7 weeks ago

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Jun 4, 2026, 10:30 AM EDT - 2 months ago

NeoGenomics Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 7:05 AM EDT - 2 months ago

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

May 21, 2026, 10:00 AM EDT - 2 months ago

NeoGenomics Transcript: AGM 2026

May 20, 2026, 4:20 PM EDT - 2 months ago

Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares

May 20, 2026, 4:15 PM EDT - 2 months ago

Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project

May 15, 2026, 9:05 AM EDT - 2 months ago

NeoGenomics to Participate in Upcoming Investor Conferences

2026-04-29T16:45:29.000Z - 3 months ago

NeoGenomics price target lowered to $11 from $13 at BofA

2026-04-29T13:42:05.000Z - 3 months ago

NeoGenomics price target raised to $14 from $13 at TD Cowen

2026-04-29T10:41:39.000Z - 3 months ago

Leerink upgrades NeoGenomics to Outperform, raises target to $25

2026-04-29T10:26:48.000Z - 3 months ago

NeoGenomics upgraded to Buy from Hold at Benchmark

2026-04-29T10:19:13.000Z - 3 months ago

NeoGenomics upgraded to Outperform from Market Perform at Leerink

2026-04-28T21:39:08.000Z - 3 months ago

NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c

2026-04-28T21:36:36.000Z - 3 months ago

NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M

Apr 28, 2026, 4:30 PM EDT - 3 months ago

NeoGenomics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 3 months ago

NeoGenomics Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 3 months ago

NeoGenomics Slides: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 3 months ago

NeoGenomics Quarterly report: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 3 months ago

NeoGenomics Reports First Quarter 2026 Results

Apr 23, 2026, 7:05 AM EDT - 3 months ago

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Apr 13, 2026, 7:05 AM EDT - 4 months ago

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Apr 7, 2026, 7:05 AM EDT - 4 months ago

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

Apr 6, 2026, 8:00 AM EDT - 4 months ago

NeoGenomics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

NeoGenomics Proxy statement: Proxy filing

Mar 16, 2026, 7:05 AM EDT - 5 months ago

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

Mar 10, 2026, 4:20 PM EDT - 5 months ago

NeoGenomics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:00 PM EDT - 5 months ago

NeoGenomics Slides: Investor presentation

Mar 3, 2026, 1:10 PM EST - 5 months ago

NeoGenomics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:05 AM EST - 5 months ago

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

Feb 17, 2026, 8:30 AM EST - 5 months ago

NeoGenomics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 5 months ago

NeoGenomics Annual report: Q4 2025

Feb 17, 2026, 8:30 AM EST - 5 months ago

NeoGenomics Earnings release: Q4 2025

Feb 17, 2026, 8:30 AM EST - 5 months ago

NeoGenomics Slides: Q4 2025

Feb 17, 2026, 7:05 AM EST - 6 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 7:05 AM EST - 6 months ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Jan 27, 2026, 7:05 AM EST - 6 months ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 13, 2026, 8:15 PM EST - 7 months ago

NeoGenomics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 7 months ago

NeoGenomics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:05 AM EST - 7 months ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

Jan 5, 2026, 7:05 AM EST - 7 months ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 7:05 AM EST - 7 months ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 15, 2025, 7:05 AM EST - 8 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 10, 2025, 7:05 AM EST - 8 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 8, 2025, 8:05 AM EST - 8 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Dec 2, 2025, 2:30 PM EST - 8 months ago

NeoGenomics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 2:00 PM EST - 9 months ago

NeoGenomics Transcript: Stephens Annual Investment Conference

Oct 30, 2025, 12:51 PM EDT - 9 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 28, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Slides: Q3 2025

Oct 28, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Reports Third Quarter 2025 Results

Oct 14, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 7, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Aug 29, 2025, 7:05 AM EDT - 1 year ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Jul 30, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Slides: Q2 2025

Jul 29, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 4, 2025, 2:00 PM EDT - 1 year ago

NeoGenomics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 1:00 PM EDT - 1 year ago

NeoGenomics Transcript: 45th Annual William Blair Growth Stock Conference

May 28, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Quarterly report: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings release: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Slides: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results

Apr 23, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing

Apr 22, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing

Apr 8, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

TwinTurboBul161 Aug. 3 at 11:31 PM

$FCHL $NEO Watching7

0 · Reply

bmwbuzzz Aug. 3 at 3:50 PM

$NEO Adding to my adding to the sentiment!!!

0 · Reply

bmwbuzzz Jul. 31 at 12:41 AM

$NEO Adding to the sentiment!

0 · Reply

BTG007 Jul. 30 at 5:56 PM

$NEO lawsuits plus they let go of their chief compliance officer- could spell trouble in the future

0 · Reply

Spicy_Trade Jul. 29 at 11:49 PM

NeoGenomics, Inc. ( $NEO ) SpicyTrade - Daily Stock Analysis https://youtu.be/mKBSi4bIVQw?si=eB_BSBcVgw68wnJT

0 · Reply

topstockalerts Jul. 29 at 8:06 PM

$NEO not chasing but definitely watching this closely

0 · Reply

Aatrader2475 Jul. 29 at 4:46 PM

$BATL $CMMB $MULN.X $NEO $SKYQ @FDI2026 what you got to say for your clown self??? LOL

0 · Reply

Stocks_Spot Jul. 29 at 4:22 PM

0 · Reply

prismmarketview Jul. 29 at 4:21 PM

0 · Reply

prismmarketview Jul. 29 at 4:16 PM

0 · Reply

STACKD0E Jul. 29 at 2:41 PM

$NEO 👁️

0 · Reply

kp8claw Jul. 29 at 2:19 PM

0 · Reply

OpenOutcrier Jul. 29 at 12:10 PM

$NEO (+13.8% pre) NeoGenomics (NEO) Tops Q2 EPS by 2c ; Offers Guidance https://ooc.bz/l/109027

0 · Reply

EarningsInsider Jul. 28 at 9:46 PM

https://www.marketbeat.com/earnings/reports/2026-7-28-neogenomics-inc-stock/ $NEO NeoGenomics Earnings Transcript

0 · Reply

StocktwitsEarnings Jul. 28 at 8:12 PM

$NEO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.02 up 105.71% YoY • Reported revenue of $201.66M up 11.21% YoY

0 · Reply

carminefox Jul. 28 at 5:47 PM

$NEO earnings coming in soon,could use a nice bump here!

0 · Reply

AnonMav Jul. 24 at 1:12 PM

$NEO In resistance zone

0 · Reply

bmwbuzzz Jul. 23 at 10:04 PM

$NEO not sure where the Extremely Bearish rating comes from 🙄

0 · Reply

HarperLucky Jul. 21 at 9:56 PM

$NEO on my radar for 20$+

0 · Reply

EpimetheusTrading Jul. 19 at 12:40 AM

Stock to watch: $NEO

0 · Reply

bmwbuzzz Jul. 8 at 4:29 PM

$CEPL Plenty of ways to add capital, dilutive and not. It is important for a growing (transforming) company to have options. I see this similar to what $NEO did last month. What appeared as a dilutive note offering was only a precursor to growth positioning (financing at a lower current market rate based on SP). Faith in the CEO/Board who have taken this out of BK without killing us stockholders off!

0 · Reply

bmwbuzzz Jul. 7 at 7:35 PM

$NEO @Kat_Harington - you're not happy with the 30% (since note issuance) 1 month return???

1 · Reply

Market Cap	1.96B
Revenue (ttm)	727.33M
Net Income (ttm)	-108.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.85%
Debt to Equity Ratio	0.00

Volume	2,973,900
Avg Vol	3,036,722
Day's Range	N/A - N/A
Shares Out	128.48M
Stochastic %K	85%
Beta	1.74
Analysts	Strong Sell
Price Target	$18.61